Fintel on MSN

Truist Securities initiates coverage of Septerna (SEPN) with buy recommendation

Fintel reports that on December 15, 2025, Truist Securities initiated coverage of Septerna (NasdaqGM:SEPN) with a Buy ...
TipRanks on MSN

Septerna initiated with a buy at Truist

Truist initiated coverage of Septerna (SEPN) with a Buy rating and $34 price target The firm says the company’s SEP-631 is in Phase 1 for chronic ...

Septerna to Participate in 8th Annual Evercore Healthcare Conference

(Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in a fireside chat at ...

Cantor Fitzgerald Sticks to Their Buy Rating for Septerna, Inc. (SEPN)

Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Septerna, Inc. yesterday and set a price target of $25.00. The company’s shares closed yesterday at $23.77. Claim 60% off TipRanks ...
WCBD

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...
WLNS.com

Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-631 in Healthy Volunteers

SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...